1. Articles in category: Drug Development

    1-24 of 37 1 2 »
    1. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    2. Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Indian Pediatr. 2017 Sep 15;54(9):765-770

      Authors: Jain R, Gupta K, Bhatia A, Bansal A, Bansal D

      Abstract Veno-occlusive disease of the liver is mostly encountered as a complication of hematopoietic stem cell transplantation with myeloablative regimens with an incidence estimated to be 13.7%.

      Read Full Article
    3. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Carcinogenesis. 2017 Aug 29;:

      Authors: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M

      Read Full Article
    4. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma

      Pediatric cancers such as neuroblastoma are thought to involve a dysregulation of embryonic development. However, it has been difficult to identify the critical events that trigger tumorigenesis and differentiate them from normal development. In this study, we report the establishment of a spheroid culture method that enriches early-stage tumor cells from TH-MYCN mice, a preclinical model of neuroblastoma.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    5. A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      Cell Syst. 2017 Sep 27;5(3):161-162

      Authors: Arora M, Spencer SL

      Abstract Live-cell imaging demonstrates that a subset of neuroblastoma cells evades chemotherapy-induced death if they are in early G1 phase of the cell cycle at the time of drug treatment and have sufficiently high levels of MYCN.

      PMID: 28957649 [PubMed - in process]

      Read Full Article
    6. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    7. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Bioorg Med Chem Lett. 2017 Sep 09;:

      Authors: Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M

      Abstract Neuroblastoma is an aggressive and drug-resistant refractory cancer.

      Read Full Article
      Mentions: Refractory
    8. Patient-derived xenografts as preclinical neuroblastoma models.

      Patient-derived xenografts as preclinical neuroblastoma models.

      Cell Tissue Res. 2017 Sep 19;:

      Authors: Braekeveldt N, Bexell D

      Abstract The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative.

      Read Full Article
      Mentions: Side Effects
    9. Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.

      Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.

      Neurochem Int. 2017 Sep 15;:

      Authors: Calvo-Ochoa E, Sánchez-Alegría K, Gómez-Inclán C, Ferrera P, Arias C

      Read Full Article
    10. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    11. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    12. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      Cancer Cell. 2017 Sep 11;32(3):273-275

      Authors: Liu Z, Thiele CJ

      Abstract LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metastatic disease progression.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    13. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    14. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      ( Children's Hospital of Philadelphia ) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

      Read Full Article
    15. RACE for Children Act Becomes Law!

      RACE for Children Act Becomes Law!

      WASHINGTON, Aug. 19, 2017 /PRNewswire/ -- Yesterday, the RACE for Children Act became law, ensuring that novel and exciting new cancer drugs will now be developed not only for adults, but also for children with cancer. Nancy Goodman, CEO of Kids v Cancer stated, "One of the greatest...

      Read Full Article
    16. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.

      Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.

      J Exp Clin Cancer Res. 2017 Aug 16;36(1):111

      Authors: Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L, Wu Z, Wu Y

      Abstract BACKGROUND: Chemotherapy is one of major therapeutic regimens for neuroblastoma (NB) in children. However, recurrence and metastasis associated with poor prognosis caused by acquired multidrug resistance remains a challenge.

      Read Full Article
    17. PRC2-mediated transcriptomic alterations at the embryonic stage govern tumorigenesis and clinical outcome in MYCN-driven neuroblastoma.

      PRC2-mediated transcriptomic alterations at the embryonic stage govern tumorigenesis and clinical outcome in MYCN-driven neuroblastoma.

      Cancer Res. 2017 Aug 14;:

      Authors: Tsubota S, Kishida S, Shimamura T, Ohira M, Yamashita S, Cao D, Kiyonari S, Ushijima T, Kadomatsu K

      Read Full Article
      Mentions: MYCN Tumorigenesis
    18. CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma.

      Read Full Article
    19. New strategy against childhood cancer

      New strategy against childhood cancer

      Neuroblastoma is a cancer in children that originates in the sympathetic nervous system and has a high mortality. Current treatment includes chemotherapy and radiotherapy with their potentially severe side effects; there is therefore an urgent need for a new improved drug. One potential treatment strategy is to use a drug to target deviant molecular signalling caused by changes in genes.

      Read Full Article
    1-24 of 37 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) MYCN
    2. (1 articles) Antibody
    3. (1 articles) ALK
    4. (1 articles) Imaging
    5. (1 articles) Tumorigenesis
  4. General Informations in the News

    1. (1 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Side Effects
    2. (1 articles) Refractory
    3. (1 articles) Stem Cell Transplant
    4. (1 articles) Chemotherapy